indication

For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures

pharmacology

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

mechanism of action

Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.

half life

2 minutes

route of elimination

In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.

drug interactions

Amitriptyline: The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dobutamine.

Amoxapine: The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine.

Clomipramine: The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dobutamine.

Desipramine: The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dobutamine.

Doxepin: The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine.

Entacapone: Entacapone increases the effect and toxicity of the sympathomimetic, dobutamine.

Guanethidine: Dobutamine may decrease the effect of guanethidine.

Imipramine: The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine.

Isocarboxazid: Increased arterial pressure

Linezolid: Possible increase of arterial pressure

Methyldopa: Increased arterial pressure

Midodrine: Increased arterial pressure

Moclobemide: Moclobemide increases the sympathomimetic effect of dobutamine.

Nortriptyline: The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dobutamine.

Phenelzine: Increased arterial pressure

Rasagiline: Increased arterial pressure

Reserpine: Increased arterial pressure